News | Radiopharmaceuticals and Tracers | September 03, 2015

Navidea Awarded $1.8M Grant for Manocept Agent Evaluation in Kaposi’s Sarcoma

Grant will cover preclinical safety trial and clinical trial evaluating detection of KS lesions with SPECT imaging

Navidea, SBIR grant, NCI, NIH, Kaposi's sarcoma, Tc99m tilmanocept, SPECT

Image courtesy of Navidea Biopharmaceuticals Inc.

September 3, 2015 — Navidea Biopharmaceuticals Inc. received initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant up to $1.8 million from the National Cancer Institute (NCI), National Institutes of Health (NIH). The grant will be used to fund preclinical studies examining the safety of intravenous (IV) injection of Tc99m tilmanocept, a Manocept platform product. This will be followed by a clinical study of the safety and efficacy of single photon emission computed tomography (SPECT) imaging studies to identify and quantify both skin- and organ-associated Kaposi’s Sarcoma (KS) lesions in human patients. 

The SBIR grant is awarded in two parts, with the potential for total grant money of up to $1.8 million over two-and-a-half years. The first six-month funding segment of $300,000, which has already been awarded, is expected to enable Navidea to secure necessary collaborations and Institutional Review Board (IRB) approvals. The second funding segment could provide for up to an additional $1.5 million to accrue participants, perform the Phase 1/2 study, and perform data analyses to confirm the safety and effectiveness of intravenously administered Tc99m tilmanocept.

“Building on earlier research showing KS tumor cells abundantly express CD206, the tilmanocept receptor, and successful imaging with subcutaneous injection, we plan to evaluate intravenous administration of this targeted imaging agent to noninvasively locate internal KS lesions, which are currently challenging to identify and monitor,” commented Toby Maurer, M.D., FAAD, professor of dermatology at the University of California, San Francisco (UCSF), and chief of dermatology at San Francisco General Hospital and Trauma Center, who is co-PI at UCSF with Michael S. McGrath, M.D., PhD. “If successful, future diagnostic and eventually therapeutic developments have the potential to dramatically improve life expectancies and quality of life for patients suffering from Kaposi’s sarcoma.”

For more information: www.navidea.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...